Yttrium [90Y] chloride

Alfa Cytology announced the significant expansion of its radiopharmaceutical portfolio with cutting-edge radiopharmaceutical-drug conjugate design services. NEW YORK, NY, UNITED STATES, October 30, 2025 / EINPresswire.com / -- Alfa Cytology, a globally recognized contract research organization (CRO) providing comprehensive, integrated solutions for drug discovery and development, announced the significant expansion of its radiopharmaceutical portfolio with cutting-edge radiopharmaceutical-drug conjugate (RDC) design services. This offering is designed to support biopharmaceutical companies in the complex process of creating novel, targeted RDCs, a rapidly growing class of therapeutics. Radiopharmaceutical-Drug Conjugates are promising in precision medicine, combining a tumor-targeting molecule (like a peptide or antibody) with a therapeutic radioisotope. This allows for the direct delivery of cytotoxic radiation to cancer cells while minimizing damage to healthy tissues. A critical step in this process is to find a suitable radionuclide , such as Lu-177 or Ac-225, whose physical half-life and radiation type (e.g., beta or alpha particles) are matched to the specific cancer type and the biological half-life of the targeting molecule. Alfa Cytology's RDC design service suite provides end-to-end support, from initial concept to pre-clinical candidate selection. "With the oncology field increasingly recognizing the immense potential of targeted radiopharmaceuticals, there is a critical need for specialized expertise in RDC design and development," said the business development manager at Alfa Cytology. "Our expanded portfolio is a direct response to this need. We are empowering our clients to overcome the unique challenges of linker chemistry, chelator selection, and radiobiological optimization to create more effective and stable RDC candidates." The advanced RDC design services include:  Radiolabeled compounds synthesis services : comprehensive radiolabeling and radiosynthesis services, from molecular labelling and pathway optimization to synthesis, analysis, and purification. Linker design and synthesis services: Expert selection and custom synthesis of optimal chelators to securely bind radioisotopes (e.g., Lu-177, Ac-225, Y-90) and stable linkers to connect the targeting and payload components. In-vitro & in-vivo evaluation: Comprehensive profiling, including stability assays, binding affinity studies, and efficacy testing in relevant disease models. "By integrating our new RDC design expertise with our established platforms, we can significantly de-risk and accelerate our clients' development timelines," added the business development manager. "We are committed to being at the forefront of the RDC revolution, helping to bring the next generation of targeted radiotherapies to patients in need." This expansion solidifies Alfa Cytology's position as a full-service partner in the radiopharmaceutical space, complementing its existing capabilities in isotope sourcing, preclinical testing, and regulatory consulting. For more information about Alfa Cytology's RDC design services, visit www.rdcthera.com . About Alfa Cytology Alfa Cytology is a globally recognized contract research organization (CRO) providing comprehensive, integrated solutions for drug discovery and development. With a focus on oncology, the company offers a suite of services spanning from target validation and preclinical studies to early-phase clinical trial support. Alfa Cytology's team of seasoned scientists is dedicated to accelerating the translation of innovative science into life-changing therapies. Toya Davis Alfa Cytology +1 516-874-2440 contact@alfacytology.com Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of minimally invasive interventional oncology solutions, today announced that it has received an expanded CE Mark approval for SIR-Spheres® Y-90 resin microspheres for the treatment of patients with liver cancer. With this expansion, eligibility now covers both primary and secondary liver metastases, increasing patient access to a well-established, targeted therapy. "This milestone is about more than regulatory approval—it's about giving hope and options back to patients facing some of the toughest cancer diagnoses," said Matt Schmidt, CEO of Sirtex Medical. "By expanding access to SIR-Spheres®, we're ensuring that more people can benefit from a well-tolerated therapy when they need it most." Radioembolization—also known as selective internal radiation therapy (SIRT)—delivers yttrium-90 directly to tumors via the hepatic artery, allowing for high-dose, targeted radiation aiming to minimize impact to surrounding healthy tissue. "Y-90 radioembolization has long demonstrated clinical value in managing complex liver tumors," said Prof. Dr. med. Jens Ricke, Director of the Clinic and Polyclinic of Radiology at the University Hospital Ludwig-Maximilians in Munich, Germany. "With this expanded CE Mark, more patients will have access to a therapy that can extend life, improve quality of life, and offer hope when other treatments may no longer be effective." The CE Mark expansion follows an extensive review of clinical data demonstrating the safety and effectiveness of SIR-Spheres® across diverse liver metastases. Together with the FDA's recent approval of SIR-Spheres® Y-90 resin microspheres for the treatment of unresectable HCC in the United States, this milestone underscores the growing global recognition of SIR-Spheres® as a versatile, differentiated therapy and reinforces the Sirtex commitment to advancing liver-directed interventional oncology. For more information and details on how to incorporate SIR-Spheres® into your practice, please contact Sirtex at [email protected]. About SIR-Spheres ® in Europe SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of: Unresectable hepatocellular carcinoma (HCC), or Unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy, or Unresectable intrahepatic cholangiocarcinoma (iCCA), or Hepatic metastases by neuroendocrine tumours (mNET), or Other liver metastases Caution: Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings and precautions. About Sirtex Sirtex Medical is a global healthcare company focused on advancing minimally invasive, liver-directed cancer and embolization therapies. With offices in the U.S., Australia, Europe, and Asia, Sirtex delivers innovative minimally invasive interventional oncology and embolization solutions to physicians and patients worldwide. For more information, visit . APM-EMEA-009-07-25 SOURCE Sirtex Medical Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED